PerformanceRiskValuationProfitabilityCashflowLiquidityESGRevenue & Geographic ExposureForecastFinancial GrowthIncome GrowthCashflow GrowthBalance Sheet Growth
Actinium Pharmaceuticals, Inc. (ATNM)
1.780.01 (-0.56%)
1.75 - 1.81
1.03 - 2.41
122.5K / 296.7K (Avg.)
-1.36 | -1.31
Helps investors judge whether earnings growth is driven by sustainable operations or temporary factors. Consistent, organic income expansion can justify a higher intrinsic value for patient, long-term investors.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
-8.17%
Both companies reducing R&D. Martin Whitman would check industry innovation trends.
28.86%
G&A change of 28.86% while TRAW maintains overhead. Bruce Berkowitz would investigate efficiency.
No Data
No Data available this quarter, please select a different quarter.
-40.21%
Other expenses reduction while TRAW shows 0.00% growth. Joel Greenblatt would examine efficiency.
6.04%
Operating expenses growth while TRAW reduces costs. John Neff would investigate differences.
6.04%
Total costs growth while TRAW reduces costs. John Neff would investigate differences.
-100.00%
Interest expense reduction while TRAW shows 0.00% growth. Joel Greenblatt would examine advantage.
-40.21%
Both companies reducing D&A. Martin Whitman would check industry patterns.
-66.22%
EBITDA decline while TRAW shows 155.32% growth. Joel Greenblatt would examine position.
No Data
No Data available this quarter, please select a different quarter.
-6.04%
Operating income decline while TRAW shows 154.64% growth. Joel Greenblatt would examine position.
No Data
No Data available this quarter, please select a different quarter.
-333.64%
Both companies reducing other expenses. Martin Whitman would check industry patterns.
-65.74%
Pre-tax income decline while TRAW shows 154.62% growth. Joel Greenblatt would examine position.
No Data
No Data available this quarter, please select a different quarter.
-100.00%
Tax expense reduction while TRAW shows 0.00% growth. Joel Greenblatt would examine advantage.
-65.74%
Net income decline while TRAW shows 154.35% growth. Joel Greenblatt would examine position.
No Data
No Data available this quarter, please select a different quarter.
-47.67%
EPS decline while TRAW shows 100.00% growth. Joel Greenblatt would examine position.
-53.82%
Diluted EPS decline while TRAW shows 100.00% growth. Joel Greenblatt would examine position.
12.14%
Share count increase while TRAW reduces shares. John Neff would investigate differences.
7.50%
Diluted share increase while TRAW reduces shares. John Neff would investigate differences.